RxDoctor Payments DataLook up a doctor →

Stephen Savage, MD

Urology · Charleston, SCNPI 1669428553

Payments from drug & device makers

$2,098,415in general payments, 2019–2025

Across 350 payments — averaging $5995.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.6M
  • Janssen Research & Development, LLC$399K
  • AstraZeneca$58K
  • Bayer$26K
  • Ferring International Pharmascience Center US$15K
  • Ferring Pharmaceuticals AS$13K
  • plus $26K from 21 others

What the payments were for

  • Consulting fees$15,57349%
  • Travel & lodging$5,49317%
  • Food & beverage$6,72621%
  • Education$4,00013%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,098,415 in reported general payments places this provider in the 95th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$243,527
Medicare patients
760
Services billed
2,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Thiola EcTiopronin12$91,851
MyrbetriqMirabegron57$34,809
GemtesaVibegron12$14,415
Potassium Citrate ErPotassium Citrate39$4,987
Tamsulosin Hcl277$4,110
Finasteride186$2,412
Methenamine Hippurate32$1,984
Alfuzosin Hcl ErAlfuzosin Hcl23$562
Oxybutynin Chloride ErOxybutynin Chloride19$372
CefuroximeCefuroxime Axetil62$174
Allopurinol11$136
Gabapentin11$42
Ciprofloxacin Hcl11$19

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$10,110$14,41512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 196 urology providers in South Carolina.

Other urology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →